Skip to main content

CJC-1295 (no DAC) vs Hexarelin

Both CJC-1295 (no DAC) and Hexarelin are used for growth-hormone and recovery. Here's how their evidence, dosing, and regulatory status actually compare.

CJC-1295 (no DAC)

Evidence B

Modified Growth Hormone Releasing Factor 1-29

A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.

View full CJC-1295 (no DAC) profile →

Hexarelin

Evidence B

Hexarelin (HEX)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

View full Hexarelin profile →

Side-by-Side

AttributeCJC-1295 (no DAC)Hexarelin
Evidence GradeBB
FDA StatusNot FDA-approved — Category 1 (compounding allowed)Not FDA-approved — research compound (cardioprotective signals investigated)
Typical Dose100–300 mcg before bed (subcutaneous)100 mcg, 1–2 times daily (subcutaneous)
Clinics Indexed15641
Categoriesgrowth-hormone, anti-aging, recoverygrowth-hormone, recovery

Key reported benefits — CJC-1295 (no DAC)

  • Growth hormone release
  • Fat loss
  • Improved sleep
  • Muscle recovery

Key reported benefits — Hexarelin

  • Strongest GH spike of GHRPs
  • Cardioprotective signals
  • Recovery

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons